Australian Journal of Opthalmology 2015-12-01

Effect of glaucoma medications on 24-hour intraocular pressure-related patterns using a contact lens sensor.

Kaweh Mansouri, Felipe A Medeiros, Robert N Weinreb

Index: Clin. Experiment. Ophthalmol. 43 , 787-95, (2015)

Full Text: HTML

Abstract

The aim of this article was to study the circadian intraocular pressure (IOP)-related effects of ocular hypotensive medications using a contact lens sensor (CLS).This is a university-based prospective, randomized, crossover trial.A total of 23 patients with primary open-angle glaucoma participated.Patients underwent ambulatory recording of IOP-related patterns for 24 h in one eye during 3 monthly sessions using a CLS. Patients were untreated in session 1 (S1), were randomized to one of four classes of glaucoma drops for S2 and had a prostaglandin analogue add-on for S3.Changes in IOP-related patterns were defined using (i) slopes from wake/sitting to sleep/supine; (ii) cosinor rhythmometry modelling; and (iii) area under receiver operating curve (AUC) of sleep period.Mean patient age was 63.8 ± 11.8 years. Positive linear slopes were seen from wake/sitting to sleep/supine at S1 (17.1 ± 14.2 mVeq/h) and S2 (5.5 ± 23.9 mVeq/h) and negative slopes at S3 (-1.9 ± 29.4 mVeq/h) (S1-S2, P = 0.01; S1-S3, P = 0.02). In the prostaglandin group, slopes changed significantly with introduction of drops (S1-S2, P < 0.024), whereas they did not in a mixed group combining the three other classes (S1-S2, P = 0.060). Overall, cosinor amplitudes were 98.4 ± 46.5 mVeq (S1), 113.0 ± 35.6 mVeq (S2) and 109.6 ± 58.3 mVeq (S3) (S1-S2, P = 0.23; S1-S3, P = 0.66; S2-S3, P = 0.93). AUC were 91.8 ± 63.0 mVeq (S1), 76.3 ± 102.7 mVeq (S2) and 19.9 ± 135.8 mVeq (S3). Differences between sessions were not statistically significant (S1-S2, P = 0.541; S1-S3, P = 0.083; S2-S3, P = 0.092).Prostaglandin analogues, but not other medications, seem to flatten the IOP-related increase at transition of the wake/sitting to the sleep/supine period, but do not seem to have an effect on acrophase and amplitude.© 2015 Royal Australian and New Zealand College of Ophthalmologists.


Related Compounds

  • Bimatoprost
  • Brimonidine

Related Articles:

A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis.

2014-10-01

[Dermatol. Surg. 40(10) , 1118-24, (2014)]

Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study.

2012-01-01

[PLoS ONE 7 , e33913, (2012)]

Expression profile of inflammatory cytokines in aqueous from glaucomatous eyes.

2012-01-01

[Mol. Vis. 18 , 431-8, (2012)]

Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system.

2011-06-01

[Br. J. Ophthalmol. 95 , 869-75, (2011)]

Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay.

2009-01-01

[Mol. Vis. 15 , 1690-9, (2009)]

More Articles...